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Atrial fibrillation [AF], the most common arrhythmia in the United States, affects an 
estimated 2.2 million people in this country alone.  The prevalence of AF grows incrementally 
with increasing age, and the majority of people living with AF are over the age of 65 years.  For 
people less than 55 years old the prevalence is 0.1%, compared to an approximate 10% 
prevalence in people over the age of 80 years.  The incidence of AF is also on the rise resulting 
in predictions for AF to affect 10 million Americans by the year 2050.
1
 This increase is likely 
due to the ongoing aging of the population and an increase in the prevalence of individuals in the 
community with one or more risk factors for developing AF.
2
 Along these same lines, people are 
now living longer with medical conditions such as diabetes mellitus and hypertension, which 
predispose individuals to developing AF. The trend of increased AF prevalence in the U.S. in 
recent years and the projected continued increase over the next few decades will raise AF to 
unprecedented levels. In fact, current projections based on data from the Framingham Heart 
Study put the lifetime risk for developing AF in this country at approximately 16% for 
individuals around 40 years of age, and up to 25% if there is a prior history of congestive heart 
failure or myocardial infarction.
2
 
Several clinical risk factors have been linked to the development of AF, particularly 
advancing age which is associated with structural changes such as fibrosis in the heart that 
predispose older individuals to AF.
3
 In addition to age, other clinical risk factors for developing 
AF include male sex, cardiovascular risk factors such as hypertension and diabetes mellitus, and 
other cardiac conditions such as valvular heart disease, prior myocardial infarction, and 
congestive heart failure.
4-6
 Along with these traditional risk factors, more recently recognized 
risk factors such as obesity and sleep apnea have also been recognized. Echocardiography has 
also allowed detection of various validated cardiac structural risk factors such as left ventricular 
hypertrophy and increased left atrial size.
7, 8
 Although race has never been considered a risk 
factor for developing AF, there is evidence to suggest that whites develop AF more than other 
racial groups out of proportion to the prevalence of the clinical risk factors mentioned here. As 
little is known about the interaction of race and AF, this paper seeks to review all relevant 
published data on race and AF.  
Many experts have called AF in this country an emerging epidemic.
9, 10
 The increasing 
prevalence of AF is important because AF is not a benign disease. Although once thought to be 
clinically unimportant and merely a nuisance to be tolerated by the individual, it is now 
recognized as a major risk factor for thromboembolic disease as well as a factor in overall long-
term mortality. The single most feared sequela of AF is an ischemic stroke due to 
thromboembolic complications from a left atrial or left atrial appendage thrombus, or possibly an 
aortic atheroma. AF is felt to be responsible for about 15% of all ischemic strokes.
11, 12
 Embolic 
strokes due to AF tend to be larger and are more likely to be fatal compared to small vessel 
strokes. Systemic embolization appears to be less common but can be equally devastating with 
resultant ischemic bowel or ischemia and necrosis of distal extremities. Embolization is one of 
the reasons why AF carries a 1.5-2-fold increase in mortality risk compared to individuals 
without AF. In fact, in large observational studies such as Framingham, AF carries long-term 
significant morbidity and mortality even when controlling for other co-morbidities such as heart 
disease and diabetes.   
Randomized placebo-controlled trials have estimated the overall risk of stroke in patients 
with AF who are not anticoagulated to be approximately 4.5-5% per year.
13
 This is a general risk 
assessment when considering all AF patients in aggregate. However, extensive research has been 
conducted looking at individual risk factors for stroke in patients with non-valvular AF to 
determine which AF patients are low risk and which are high risk for thromboembolic 
complications. This has important clinical implications for patients with AF since these clinical 
risk factors help stratify the risk of stroke and tailor anticoagulation therapy for individual 
patients. Similar to the risk factors for developing AF in the first place, congestive heart failure, 
hypertension and advanced age (i.e. greater than 75 years old) are all known risk factors for 
ischemic stroke in AF patients. Additionally, known diabetes mellitus and a history of prior 
stroke are also known to elevate the risk for thromboembolic complications.
2
 These are currently 
the main risk factors considered when determining the need for anticoagulation in a patient with 
AF.  
It is not surprising that AF is a burden on the healthcare system as well as the individual 
given that it is a chronic disease which can be refractory to treatment. The management of AF 
often involves various diagnostic studies, pharmacologic treatments and long term management 
with anticoagulation therapy. AF can also have a synergistically negative effect on overall health 
when combined with other cardiovascular diseases. For example, in patients with well controlled 
heart failure due to systolic or diastolic dysfunction, AF can precipitate an exacerbation that may 
require admission to the hospital.  Similarly, AF with rapid ventricular rate can contribute to 
active coronary ischemia in a patient whose ischemia burden is typically well controlled.   
Although multiple prior studies have closely scrutinized the relationship between the 
development of AF and age, gender, and multiple medical conditions, only recently has race or 
ethnicity been mentioned as a possible “risk factor” worth investigating. Relatively little is 
known about varying susceptibility to AF, or differences in incidence and prevalence among 
different ethnic groups. It is unknown if race truly affects AF rates or whether there is a different 
pattern of AF expression. It is also unknown if the risk of stroke varies for AF patients of 
different ethnic populations. We therefore sought to perform a systematic review of all clinical 
studies looking at ethnicity as a risk factor for developing AF, and as a risk factor for ischemic 




Methods for Systematic Review of the Literature: MEDLINE and The Cochrane Database 
of Systematic Reviews were searched for abstracts, papers, clinical trials and reviews. Four 
primary PubMed searches were performed using the following search terms: (1) MeSH term 
atrial fibrillation with subheading ethnology yielded 31 articles written in English. (2) MeSH 
terms atrial fibrillation and continental population groups (i.e. race) yielded 69 studies, all of 
which were redundant from MeSH search (1) or irrelevant to our focused interest. This search 
yielded one additional publication of interest. (3) MeSH terms atrial fibrillation, ethnicity and 
epidemiology yielded 3 additional relevant studies out of 44 total publications. (4) MeSH terms 
atrial fibrillation and stroke with subheading ethnology yielded another two relevant studies out 
of ten total. Although no limits were used for publication date, all the Medline articles included 
were published between 1997 and 2008. The Cochrane Database search was done in three ways, 
using atrial fibrillation as a keyword, as a review topic, and as a MeSH term. This resulted in no 
relevant articles that analyzed racial or ethnic differences with respect to atrial fibrillation. We 
also used references obtained from bibliographies in articles generated from the MEDLINE 
searches.  
Due to the general paucity of data on the interaction between ethnicity and atrial 
fibrillation and between ethnicity and stroke, we considered all study types and any date of 
publication. Although there were no pre-specified criteria for selection of trials in terms of trial 
design, trials that tested a surgical procedure, a catheter ablation procedure, a pacemaker, or an 
antiarrhythmic drug were excluded. Trials and observational studies that included race/ethnicity 
as part of the demographic information studied were emphasized. Studies that did not analyze by 
race, either because few non-white patients were included, or because they did not choose to 
look at race, were excluded. For example, the Framingham cohort was not included since few 
non-white participants were included and no analysis by race was done.  Since no intervention 
was assessed, data from only one randomized controlled trial were felt to be relevant. Although 
no limits for publication dates were pre-specified, all studies were conducted between 1990 to 
present with the exception of the Framingham database studies since Framingham data collection 
began in 1948. All studies included adult subjects only; no pediatric populations were included 
in this review.  Searches were restricted to the English language. Studies based in racially 
homogenous countries that did not enroll non-Caucasian subjects or subjects of African descent 
were excluded. The references of the selected publications were also reviewed for additional 
studies and publications. 
A total of 18 population-based longitudinal cohort studies, 5 of which were retrospective 
studies, 2 cross-sectional studies, and 1 post-hoc analysis of a prospective randomized controlled 
trial were included. In addition, 8 articles including reviews and editorials met the search term 
criteria. The two outcomes for analysis and review were (1) development of atrial fibrillation in 
the general population including individuals with hypertension and other predisposing 
conditions, and (2) occurrence of ischemic thromboembolic stroke in patients with atrial 
fibrillation. One reviewer collected the data. Two additional readers reviewed the studies and 
their results.  
 
Methodological quality assessment 
The method for determining the quality of the trial or cohort study was a combined 
assessment of study quality, internal validity, and handling of confounding variables. The 
assessment rating was largely based on the 2001 Center for Reviews and Dissemination (CRD) 
Report 4 which focuses on the quality assessment of cohort studies.
14, 15
 The level of evidence 
was not specifically rated in this review since none of the studies were randomized controlled 
trials, and almost all studies were either cross sectional or observational studies. The checklist of 











Table A. Quality Assessment Checklist**  
1. Are the groups being compared and the confounding variables adequately described?  
a. Are the groups reasonably similar at baseline (comorbidities, age)? 
b. Were the groups comparable on confounding variables?  
c. Are the groups at a similar point in disease progression?  
2. Was there adequate adjustment for the differences and confounding variables?  
3.  Are the inclusion/exclusion criteria reasonable?  
4. Was bias (selection, performance, measurement, attrition) present? 
5. Were the drop out rates similar between groups and at an acceptable level? Were all 
participants accounted for at the end of the study? 
5. Does the study have internal validity? 
a. Adequate sample size to detect difference? 
b. Was a power calculation done? 
c. Prevention of systematic errors or bias? 
6. Was the follow up long enough and did the entire cohort have follow-up? 
7. Was the determination of race done reliably, consistently, clearly described? 
8. Are the enrolled subjects representative of the population at large? Is there sufficiently broad 
representation of the population who is at risk for developing atrial fibrillation?  
9. Was the cohort followed prospectively? 
10. Was the detection and diagnosis of Afib made reliably and equally between groups? 
** This is a modified checklist for observational cohort studies based on the Centre for Reviews and Dissemination 




Eighteen publications met the primary search term criteria. Of these, eleven looked at 
race and atrial fibrillation, and seven looked at race and stroke etiology. Studies that had multiple 
publications over time were only counted once.  There were no randomized controlled studies 
that fit our search criteria; most studies included were prospective observational or retrospective 
cross sectional studies. The Framingham Heart study was not included since it consists of a 
predominantly white cohort and was never analyzed for ethnic differences in lifetime risk of 
AF.
2, 16
 The landmark randomized controlled studies that compared different anticoagulation 
strategies in AF patients were not included in this review because either a breakdown of the 




 Quality Assessment: The source population in the studies reviewed here which looked at 
AF incidence and race often were adequate and appropriate in that they were large studies using 
a comprehensive database. The biggest problem with some of these observational studies was the 
low enrollment of non-white subjects which can make conclusions or even the formulation of 
hypotheses difficult. For example, the ATRIA study, whose source population was Kaiser HMO 
patients with non-transient AF, blacks made up only 3.6% of the total cohort. The VA study by 
Borzecki et al used the 1999 Large Health Survey of Veteran Enrollees post-hoc and had 12% 
black enrollment which is reasonably large. However, it was a survey study which makes it 
prone to non-respondent bias. Cohort studies that collected the data prospectively were 
considered to be of higher quality than studies which collected the data post-hoc. Regardless of 
data collection method, the studies in this review which were observational were certainly prone 
to bias. Since the groups were not determined by random allocation, selection bias is a concern. 
Furthermore, given that the groups were determined based on race, the groups may vary by 
socioeconomic status or access to healthcare. The studies using the Kaiser HMO dataset should 
not have some of the concerns with systematic differences between the white and black subjects 
in the sense that access to healthcare and detection of Afib should be relatively similar. However, 
generalizability of the source population may be of concern, Bias may also result due to 
misclassification of race. There was no unifying method for race determination. Some studies 
used patient self reporting where other studies relied on the demographic data from the electronic 
medical record. The data collection regarding race was also fairly simplified, where persons of 
mixed heritage were reported as a single race. This certainly oversimplifies the complicated issue 
of genetic heritage and may classify a person as black or white when in fact they may classify 
themselves as Indian or of mixed descent. 
Description of Studies:  
Studies on race and AF: There were 3 prospective observational studies, and one post-
hoc analysis of a prospective randomized controlled trial. The Cardiovascular Health Study was 
the only multi-center prospective trial that looked at the incidence of AF. The other studies 
looking at the role of ethnicity in developing AF were 6 retrospective cross sectional studies and 
1 Meta-Analysis of seven randomized controlled trials (Table I).  The studies looking at race and 
AF were conducted in the U.S. and therefore the patients designated as being Black or African 
American in these studies resemble the African American demographics of this country. The 
mean age of participants in ten of the eleven studies from Table I (excluding the EKG database 
study which ranged from 20 years to 99 years old) ranged from 55 to 80 years old. Women made 
up 43% to 58 % of the participants in these trials except for the VA study which was 100% male.  
Enrollment dates for these studies ranged from 1996-2000 except for the Cardiovascular Health 
Study which used data from 1990-1993 to determine incidence of AF in that cohort, and the 
EKG study which looked at EKGs from 1996-1998 at a single institution.   
Studies on race and stroke: Of the 7 studies looking at stroke and race, two were 
prospective observational studies, one was a prospective registry, and two were post hoc 
analyses of prospectively collected data. (Table III). These studies looked at racial differences in 
risk factors for AF, prevalence of AF at time of stroke, and stroke subtype.  Some of these 
studies were conducted in England and the non-white patients were typically of African, 
Caribbean, or South Asian descent. The mean age of participants in these 6 studies ranged from 
67-80 years old.  Women made up 39-54% of the enrollees in these studies. Enrollment dates 
ranged from 1990-2005. Only two studies examined the risk of ischemic stroke or intracranial 
hemorrhage in AF patients over time (The AFFIRM outcomes analysis by Bush et al and the 
Kaiser Permanente retrospective analysis by Shen et al, both listed in Table III).
22, 23
 The other 
studies looking at the role of ethnicity were stroke studies that calculated the prevalence of AF in 








18 studies met 
inclusion criteria 
11 studied race and AF 
7 studied race and 
etiology of stroke 
 
 3 prospective observational studies 
 5 retrospective cross sectional studies 
 1 retrospective case control study 
 1 Meta-Analysis of 7 randomized 
controlled trials 
 1 post hoc analysis of the RCT LIFE 
2 prospective observational studies 
1 prospective Registry  
1 post hoc analysis of the RCT AFFIRM  
1 post hoc analysis of prospective registry 
2 retrospective cohorts 
 
 African American Race and Risk Factors for developing AF 
Since the early 1990’s, many large clinical studies like ARIC (Atherosclerosis Risk in 
Communities) sponsored by NHLBI and NHANES (National Health and Nutrition Examination 
Survey) have repeatedly demonstrated that  African Americans have a greater prevalence than 
whites of the comorbidities associated with the development of AF. These include hypertension, 
ventricular hypertrophy, and diabetes. The greater prevalence of these risk factors for AF in 
black subjects has been shown in various types of studies with various disease states being 
investigated from hypertension to heart failure, to stroke.  For example, it has been shown that 
left ventricular hypertrophy is more prevalent in blacks than whites whether assessed by MRI, 
echocardiography or by EKG
24
 and is quite common in both black men and women. Many 
studies have shown that the prevalence of type II Diabetes Mellitus is greater in blacks compared 
to whites, but the ARIC Study also showed that the incidence of diabetes is greater as well.
25
 
And a recent systematic review of cardiovascular risk factors reviewing 16 studies found that 
blacks had higher rates of hypertension and diabetes.
26
  
In the AFFIRM trial which enrolled patients with known AF and moderate risk factors 
for stroke, although African Americans only comprised 6.6% of the cohort, a retrospective 
analysis did look for racial differences in risk factors. The AFFIRM data showed that African 
Americans with AF were significantly younger (65.7 vs. 70.3) and that they were more likely to 




Population studies have also shown that medical conditions which elevate risk of AF 
such as hypertension and diabetes are in fact more prevalent in the African American community 
than the Caucasian community. A comprehensive review of secular trends of hypertension over 
the past four decades shows that African Americans consistently have had a greater prevalence 
of high blood pressure compared to whites. Although the gap seems to be narrowing 
significantly in the recent past, overall, hypertension is still more prevalent in African 
Americans.
27
 Recent data from NHANES and NHLBI estimate that hypertension affects 
approximately 32% of non-Hispanic white adults and 44% of non-Hispanic black adults.
28
  
Estimates of diabetes prevalence broken down by ethnic group are provided by the CDC 
sponsored National Health Interview Survey (NHIS) which surveyed individuals from 2004 to 
2006. This survey of people which included adults over 20 years old revealed that 6.6% of 
whites, 7.5% of Asians, 10.4% of Hispanics, and 11.8% of blacks have known diabetes.
29
 A 
study looking at a sample of Medicare beneficiaries aged 67 or older also showed that although 
the prevalence of diabetes is increasing across the board, it is most prevalent in blacks and 
Hispanics.
30
 And probably for a multitude of social, economic and individual factors, the number 
of deaths attributed to diabetes per 100,000 population for blacks is twice that compared to 
whites (47.0 versus 22.5).
31
 
Smoking, a risk factor for overall cardiovascular health, also has varying prevalence 
among the different racial groups. Studies have demonstrated that the rate of new smokers is 
greater for blacks than whites, and conversely the rate of smoking cessation is less for blacks. In 
the 10 year longitudinal CARDIA study which began in 1985, African American men and 
women had higher smoking prevalence rates, higher smoking initiation rates and lower cessation 
rates than whites. The cause for this was felt to be largely socioeconomic. The smoking rates for 
Blacks and Whites as of 2007 are 21.5% and 19.7% according to the national BRFSS telephone 
survey.   
In summary, the well known risk factors for developing AF such as hypertension and 
diabetes mellitus are more common in blacks than whites in this country. The reasons for this are 
likely multifactorial, including socioeconomic factors, access to healthcare, as well as genetics. It 
seems logical to infer that AF would be more prevalent in blacks than whites, but this is not what 
is demonstrated in the studies looking at this.  
 
The Racial Paradox with AF 
Given the well reported racial discrepancy in disease states such as diabetes and 
hypertension, when researchers at the Kaiser Permanente Health Maintenance Organization 
(HMO) recognized that the prevalence of AF among different racial groups was quite variable, 
and in particular whites had a much higher prevalence compared to blacks, this seemed 
paradoxical.  Why would a group of patients with a greater prevalence for many of the AF risk 
factors have a lower incidence or prevalence of AF? They used their Kaiser Permanente database 
of northern California to look at the prevalence of AF in roughly 1.9 million people. They 
specifically looked at AF incidence in patients over 50 years old and compared black patients to 
white patients within the HMO. AF appeared to be more common in whites than blacks (2.2% 
vs. 1.5% p<0.001).
32
 They also broke down the cohort by 10-year increments and showed that 




 decade of life. For patients 
between 80-89 years old, the AF prevalence was 9.9% vs. 7.7% respectively (p=0.001). 
Although these are crude rates that are unadjusted for co-morbidities, this helps to dispel the 
possibility that the smaller prevalence of AF for African Americans in many trials and 
observational studies is in large part due to the younger age of the black cohort compared to the 
white subjects.  
In terms of correlating risk factors for AF to actually developing AF, The Losartan 
Intervention for Endpoint Reduction in Hypertension (LIFE) study is another large dataset of 
patients with essential hypertension and LVH that was analyzed post hoc for AF incidence in 
8831 black and white patients.
33
 They hypothesized that a reduction in LVH would translate into 
a reduction in AF incidence. Interestingly, a marker of LVH (the Cornell voltage-duration 
product) during treatment was found to be a strong predictor of AF only in the non-black 
patients. Black patients also had a lower incidence of new-onset AF compared to whites (4.8% 
vs. 8.1% p=0.007). The fact that LVH was not a predictor of AF in blacks may have been due to 
the much lower prevalence of AF in blacks or less likely due to a higher prevalence of other risk 
factors for developing AF in this group.
8
  
It has been shown in large observational studies that patients with AF do have an 
increased overall mortality risk when compared to similar patients without AF.
16
 It has also been 
shown in congestive heart failure (CHF) studies that CHF and AF in combination synergistically 
confer a high mortality. Studies have shown that blacks with CHF tend to have higher mortality 
rates than whites with a similar degree of heart failure.
34, 35
 Again, the researchers at Kaiser 
Permanente asked an important question: Is it possible that the AF paradox reverses in the CHF 
population and an increased prevalence of AF is a contributor to the increased mortality seen in 
blacks with CHF compared to whites? They looked at all Kaiser patients admitted to any of 
sixteen Kaiser hospitals in northern California with a diagnosis of CHF between July 1, 1999 and 
June 30, 2000 (the EPOCH study). Among 1,373 patients with CHF, 37% had AF. However, 
when broken down by race, the prevalence of AF in the African American cohort was 20% 
compared to 38% in the white cohort (p<0.001).
36
 This is despite a significantly greater 
prevalence of hypertension and an equal prevalence of diabetes. The Black cohort was younger 
than the white cohort (mean of 67 vs. 74 years respectively) however this was adjusted for in 
their multivariate model where race persisted as a significant factor.  
These results were corroborated by the Yale CHF study which looked at roughly 400 
consecutive CHF admissions to Yale hospital. African Americans comprised 21% of the cohort. 
Similar to the EPOCH study, African Americans tended to be younger with a greater prevalence 
of hypertension, and a significantly lower prevalence of AF at the time of admission (28% vs. 
14% p=0.01).
37
 In addition, whites were more likely to develop AF prior to discharge from the 
hospital (16.6% versus 7.3%, p=0.04). Another smaller prospective observational CHF study 
with 163 patients also found that the African American patients were younger (64 vs. 71 years 




 A Veterans Affairs  study retrospectively merged two large databases and picked a 
random sample of 1.4 million veteran enrollees who were included in the study by returning a 
mailed questionnaire.
39
 They had over 650,000 respondents and roughly 5% were Black. The 
prevalence of AF was 6.1% in Caucasians, 2.6% in African Americans, 2.6% in Hispanics, and 
3.4% in Asians. The Odds Ratio for having AF in whites was greater than all other ethnic groups 
and the biggest difference was in comparison to the black cohort (OR 1.84).  
 The paradox between prevalence of AF risk factors and prevalence of AF in the African 
American community has also been shown in an electrocardiography (EKG) study where 
everyone who had an EKG as part of their evaluation was included. Only gender and age were 
known, not medical conditions or duration of the arrhythmia. Still, the cohort was approximately 
40% black lending itself to a reasonable comparison. Looking at all ages combined, the 
prevalence of AF on the EKG was 2.5% for blacks and 7.8% for whites (p<0.001).
40
  
 Lending even more evidence that Blacks may truly develop AF less often than Whites do, 
a study compared Black and White patients with Alzheimer’s disease. Similar to the stroke 
studies that show racial differences in AF prevalence in a group that shares a medical condition 
in common i.e. stroke, this study shows the racial differences in medical co-morbidities in an 
Alzheimer’s cohort. Again, Blacks had a greater prevalence of hypertension and a significantly 
lower prevalence of AF.
41
  
 The various studies have looked at a general medicine cohort, a CHF cohort, stroke 
patients, and even Alzheimer’s disease and regardless of the underlying medical conditions, 
African Americans consistently have a lower burden of AF than their Caucasian counterparts 
even after adjustment for potential confounding factors such as age. It does not appear to be 
simply a discrepancy in the detection of AF or an increased incidence of mortality in black 
subjects with AF. The underlying reason is still unknown.  
 
Asian Race and Risk for developing AF 
The risk of developing AF in the Asian community in this country has not been well 
studied. There are only a few studies that actually separated the Asian patients from the other 
non-white patients for analysis purposes. The large VA outpatient database study mentioned 
previously was mostly white, but Asians did comprise 3.6% of the study cohort.
39
 Asians had a 
similarly low incidence of AF as Blacks did (3.6% vs. 3.4% respectively compared to 5.7% for 
whites). The odds ratio for AF by race was 1.4 for whites compared to Asians.  
 One EKG database study out of a public hospital in San Diego looked at over 80,000 
EKGs and approximately 4,000 had a diagnosis of AF, 737 of which correlated to a first time 
hospitalization.
42
 Asian patients comprised 11% of these 737 EKGs. When looking at these AF 
patients, the Asian patients were similar in age to the white patients and had similar rates of 
diabetes. However, there was a significantly greater prevalence of left ventricular hypertrophy by 
EKG criteria in Asians corresponding to an odds ratio of 2.76 for hypertrophy. One possible 
explanation is that Asians share the well known risk factors for AF, but in addition, ventricular 
hypertrophy plays a more prominent role in terms of risk stratification. A recent meta-analysis of 
seven large acute coronary syndrome trials looked at the frequency of AF in patients with acute 
coronary syndromes over time also found a lower frequency of AF in Asians compared to 
Whites (4.7% vs. 7.6%, p<0.001). This analysis included over 94,000 patients total with 1,735 
being of Asian descent.
43
 Asian patients tended to be younger but with a greater prevalence of 
diabetes. Unfortunately, ventricular hypertrophy was not investigated in this analysis. Another 
limitation of this analysis is that under the designation “Asian” are pooled together Chinese, 
Japanese, Korean and various other Asian nationalities making the Asian group probably quite 
heterogeneous and certainly limits the use of ethnicity as a surrogate for possible genetic 
differences.  
A population based study in China examined the prevalence of AF in their community.
44
 
This was a population screening of almost 2,000 Chinese people and the overall AF incidence 
was quite low at 1.5%. Again this was just an observational study, and conducted outside the 
U.S. Another observational study out of mainland China demonstrated a prevalence of AF of 
0.65%, which is lower than the U.S. prevalence despite a much greater prevalence of rheumatic 
heart disease.
45
 This limited data does suggest that Asians too have a diminished incidence and 
prevalence of AF compared to whites.  
These data highlight the importance of enrolling various minorities in these observational 
studies, not just black and white, who may have a different prevalence and incidence of AF. 
Only then can it be further delineated if there is in fact a true difference in susceptibility to AF 
among the various racial groups. Although difficult to do in this country due to small sample 
size, keeping the many ethnic groups separate rather than lumping them together under “Asian” 
would provide further data of potential differences in risk factors for AF and prevalence.   
 
Hispanic Race and Risk for developing AF 
The data on AF in the Hispanic community as compared to whites or blacks is also very 
limited. Again, the only large cohort to look at the prevalence of AF in Hispanics was the 1999 
Large Health Survey of Veteran Enrollees. As in other studies, whites were significantly older 
than the other racial groups. The mean age for whites and Hispanics were 65 and 61 years 
respectively. When adjusted for age, AF prevalence was only 3.0% in Hispanics, which was 
significantly lower than the 5.7% in whites.
39
 This corresponds to an OR for AF of 1.77 for white 
versus Hispanic subjects. While whites had a greater prevalence of conditions considered risk 
factors for AF such as coronary disease and valvular disease, Hispanics had the highest 
prevalence of diabetes mellitus (27.5%). The authors maintain that there is a racial variation and 
that there may be a genetic basis for this difference.  
 When looking at the AFFIRM Trial which only enrolled subjects with AF, only 3.3% 
(132 subjects) were Hispanic making comparisons limited. In terms of baseline characteristics, 
Hispanics were younger than whites (65 vs. 70 years, p<0.001). Despite their younger age, 
Hispanics were sicker in that they were more likely to have a history of cardiomyopathy with a 
depressed ejection fraction or heart failure. It isn’t described whether Hispanics and whites had 
comparable rates of hypertension and diabetes. Therefore, it is unclear if any differences exist 
based on this dataset, however it suggests that ventricular dysfunction may play a greater role in 
Hispanics for development of AF. Given the small enrollment of Hispanics in this trial, it is 
difficult to draw definitive conclusions and in fact seems to raise more questions regarding racial 
differences of AF since rhythm control reduced mortality in the Hispanic cohort only and not the 
other groups.  
 The Northern Manhattan Stroke Study was the first to look at stroke patients from a 
multiracial community and determine racial differences in stroke risk factors.
46
 This study was 
based on an ongoing prospective registry of all acute stroke patients who present to the urban 
Presbyterian Hospital of New York City which has a large black and Hispanic patient 
population. Hispanics had a significantly lower prevalence of AF compared to whites (4% vs. 
8%) despite having a greater prevalence of hypertension and diabetes. The authors also 
calculated the population attributable risk for individual risk factors including AF. The 
attributable risk of AF as a cause of stroke was very high in whites and essentially zero in blacks 
or Hispanics. The majority of strokes in the Hispanic group were attributed mostly to 
hypertension, diabetes and physical inactivity. Although whites were older, the comparison 
groups were matched by age, so this should not be a factor in the differences.  
Both the AF cohort and the stroke cohort studies showed that similar to blacks, Hispanics 
tended to be younger than whites, with a greater prevalence of hypertension and diabetes yet a 
lower prevalence of AF. Although this is complicated by the heterogeneity of the Hispanic race 
in the U.S., the numbers tend to be too small to separate out the differing ancestries among the 
subjects grouped as Hispanic. Similarly, although whites comprised the majority, they were not 
separated by ancestry either, and there is most likely some heterogeneity among the whites as 
well. Nonetheless, the trend seems consistent when looking at patients with AF or at patients 
with stroke and their risk factors.  
 
Risk of Stroke in patients with AF 
There are over 750,000 new strokes in this country every year.
47
 The prevalence of stroke in the 
Original Cohort from the Framingham Study was 18% over a 51 year follow up period, and the 
overwhelming majority of these strokes were  ischemic in nature (86%).
48
  In the ARIC 
population study sponsored by NHLBI, the biggest risk factors for having a stroke were 
hypertension, smoking and diabetes mellitus.
12, 49
 AF is also a well known risk factor for stroke 
and felt to approximately increase the risk of stroke for an individual by five-fold.
50
 Although the 
pathophysiology of stroke in the setting of AF is still somewhat unclear and likely multifactorial, 
it is believed that the majority of strokes are due to cardiac embolism, either from the left atrium 
or more likely the left atrial appendage. In the landmark SPAF trial conducted in the late 1980’s, 
patients with AF were randomized to either warfarin, aspirin or placebo.
18
 The combined rate of 
stroke and systemic embolism was 7.4% in the placebo arm. When looking at the SPAF III trial 
results for patients with AF with no prior stroke and only on aspirin therapy, there were 48 
strokes in 1073 patients over 1.8 years, or a rate of 2.5 strokes per 100 person-years.
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 The more 
recent AFFIRM trial where patients were anticoagulated with warfarin had an overall stroke rate 
of 6.3%, of which approximately half were believed to be embolic in nature.
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 Although the 
medical community tends to  extrapolate the stroke risk in these studies to all patients, the 
overwhelming majority of enrolled subjects in SPAF I, III and AFFIRM were white and male, 
with blacks comprising only 6% and the combined group of Hispanics, Asians and “other” 
comprising 10% of the total cohort. 
 It is worth noting that in aggregate, for patients with AF, approximately one third of 
strokes are not cardioembolic. There is more recent data that perhaps some of these are due to 
aortic atheroma embolization. And the SPAF trials showed that warfarin is ineffective for 
preventing non-cardioembolic strokes. It therefore stands to reason that for patients who have AF 
but are at greater risk for a non-embolic stroke, the risk benefit ratio of warfarin therapy may 
vary from what is quoted in the AF Guidelines.     
 
Pathophysiology of hypertension and diabetes in ischemic stroke  
Looking beyond the risk of stroke in all-comers with AF, the risk of stroke in a given 
individual patient with AF is very dependent on their co-morbidities. There are different risk 
stratification schemes to assess whether a given individual with AF is at high, intermediate, or 
low risk for thromboembolic complications. One of the most widely used scoring systems is the 
CHADS2 score which assesses risk of stroke based on the presence of; cardiac failure, 
hypertension, age >75 years, diabetes, and history of prior stroke.
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 Just as advanced age and any 
co-morbidity listed above tend to increase the risk of developing AF, they also increase the risk 
for stroke in patients who are living with AF. Although the potentiation of stroke risk by these 
individual co-morbidities in AF patients is well documented in the literature, the 
pathophysiology behind the increased stroke risk in patients with AF is not as well described. 
Hypertension, the most common risk factor for stroke in patients with and without AF, 
probably causes an ischemic stroke by aggravating cerebral atherosclerosis and increasing 
vascular resistance in arteries and arterioles over time. These structural changes protect the 
cerebral circulation in the short term but impair its ability to vasodilate predisposing to ischemia 
in the long term. The small caliber vessels seem particularly prone to hypertension-induced 
morphological changes such as microaneurysms, which then can rupture or become occluded.
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 Diabetes mellitus is also a common comorbidity in patients with stroke. Nearly twenty 
percent of stroke patients have diabetes mellitus. One probable cause for the association between 
diabetes and stroke is the known effects of diabetes on vascular endothelial function and the 
accelerated development of atherosclerosis.
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 Diabetes has also been shown to increase blood 
viscosity, platelet aggregation and elevated levels of clotting factors which can predispose to 
vessel thrombosis or embolization as well as possibly accelerate the atherosclerotic process.
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One pertinent example of diabetes induced vasculopathy is nephrotic proteinuria. Diabetic 
patients with proteinuria have a higher risk of ischemic stroke than diabetic patients without 
proteinuria, alluding to the fact that proteinuria is a marker for a systemic derangement of the 





Risk of Stroke in African Americans 
Blacks have a higher stroke rate in this country compared to whites and Hispanics.
27
 The 
Behavioral Risk Factor Surveillance System (BRFSS) is a state-based system of telephone health 
surveys that was established in 1984 and sponsored by the Centers for Disease Control (CDC). 
The 2005 BRFSS Survey found that whites and Hispanics have a similar overall prevalence of 
stroke at 2.3% and 2.6% respectively, while Asians/Pacific Islanders have a lower prevalence at 
1.6% and blacks have a higher prevalence at 4.0%.
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 Although other studies have shown 
Hispanics to have a greater prevalence of strokes compared to whites, the data have consistently 
shown blacks to have a significantly greater prevalence of stroke compared to whites.  
According to data from ARIC and NHLBI, the risk of a first stroke is almost twice as 
great for African Americans than whites. As African Americans tend to have less AF but more 
strokes than whites, it is not surprising that the etiology of the stroke was also shown to be 
different between ethnic groups with blacks having a three-fold higher risk for lacunar, non-
embolic ischemic strokes. The South London Community Stroke Registry included 1254 first 
strokes between 1995 and 1998. Approximately 80% were white and 16% of participants were 
black. Similar to data in the U.S., the black stroke patients had significantly less AF but greater 
hypertension and diabetes mellitus. The black patients were also quite younger than their white 
counterparts (63 years vs. 74 years p=0.001).
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 A subsequent study from London (the South 
London Ethnicity and Stroke Study) again demonstrated higher prevalence of hypertension, 
diabetes, and obesity but lower prevalence of MI and AF in the African and Caribbean 
community (all with p< 0.01).
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 Accordingly, the number one etiology of ischemic stroke in 
black patients was small vessel disease and in whites it was a cardioembolic source. The 
pathophysiology of small vessel disease is not fully understood, but the biggest risk factor for 
developing small vessel disease is hypertension.  
Although the black patients in this cohort were mostly first generation immigrants from 
the Caribbean which may be different than the African Americans in the U.S., similar data has 
come from the Northern Manhattan Stroke Study already mentioned. Blacks had a significantly 
greater prevalence of hypertension and LVH compared to whites and a significantly lower 
prevalence of AF (11% vs. 29% p<0.01). The subsequent case control study showed that AF 
correlated to a 2.5 times greater risk of stroke overall (OR 2.5, p=0.0001) when controlled for 
age, sex, and ethnicity. Again there were similar discrepancies in AF prevalence with Blacks at 
5% and whites at 8%. When broken down by race, ethnic-specific odds ratios for AF as a risk 
factor for stroke were seen (OR for whites=4.4 and OR for blacks =1.7). Blacks were younger 
than Whites similar to other stroke registries such as the London Registry (70 years vs. 80 years 
p<0.01)
61
  but it is important to note that the lower prevalence of AF in the black cohort cannot 
be explained by their younger age since the ORs were calculated while matching for age.
46
 When 
the investigators looked at the etiology and subtype of ischemic stroke among the different ethnic 
groups, whites had a significantly greater proportion of cardioembolic stroke than blacks 
(p=0.03) although the absolute incidence rate of all ischemic stroke subtypes was higher in 
blacks compared to whites.
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 This is consistent with prior reports that blacks overall have a 
greater stroke incidence than whites but AF as a contributing cause of the stroke is more 
problematic for whites than blacks.  
 
Risk of Stroke in Hispanic Americans 
The Northern Manhattan Study mentioned previously, which is one of the first stroke 
studies to include a large Hispanic cohort, showed that the annual age adjusted incidence of first 
ischemic stroke of any type was almost twice as great for Hispanics as for whites. And although 
whites had a greater prevalence of AF and greater proportion of cardioembolic strokes than 
Hispanics, Hispanics had higher relative rates of all ischemic stroke subtypes, including 
cardioembolic (relative rate =1.42).
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 This contrasts with the BRFSS findings from the CDC and 
a small prospective study looking at racial differences in stroke type, which both found that the 
stroke type rates were not different between whites and Hispanics.
63
  
Looking at a Hispanic-only cohort, one study conducted in Chile found that hypertension 
was the most common risk factor for stroke, and that the most common stroke type was small-
vessel disease. Although AF was the most common reason for cardioembolic stroke type, 
cardioembolic strokes were one third less common than small vessel strokes in this cohort.
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A large Medicare cohort study looked at the risk/benefit ratio of warfarin therapy in 
patients with AF. The unadjusted analysis showed that for AF patients taking warfarin, the stroke 
rate for Hispanics was more than twice that for whites. Although warfarin appeared to reduce the 
incidence of ischemic stroke by 35% compared to no antithrombotic therapy for the total cohort, 
this stroke reduction benefit was not apparent for Hispanics and blacks.
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  In fact, warfarin did 
not appear more protective than either aspirin or no antithrombotic therapy for the black and 
Hispanic Medicare recipients. Unfortunately, these data are somewhat difficult to interpret since 
no data was provided on INR levels, or percent time that an individual had a therapeutic INR. 
Although the authors did control for frequency of INR monitoring, they did not have the actual 
INR values. Additionally, only the incidence of ischemic stroke was reported, and this was not 
broken down into embolic and non-embolic etiologies. Therefore, it remains unclear if the higher 
stroke rate seen in Hispanics was due to inadequate monitoring, or due to an increased incidence 
of non-embolic strokes which are less preventable with therapeutic anticoagulation.  
A smaller study from Houston, Texas of approximately 400 subjects (the BASIC Project) 
compared ischemic stroke subtypes between Mexican Americans to non-Hispanic whites. The 
Mexican subjects were younger and with a significantly greater prevalence of diabetes. Although 
they found no difference in the distribution of ischemic stroke subtype between the two groups, 
cardioembolic stroke was 16% for Mexican Americans versus 26% for Caucasians.
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 Although 
the authors concluded that this does not represent a difference in stroke subtype between the two 
groups, it is worth noting that Mexican Americans had far fewer embolic strokes despite an equal 
prevalence of atrial fibrillation (11% versus 16% p=0.14). The difference in AF prevalence and 
cardioembolic stroke may have been statistically significant if the study was better powered and 




 Risk of Stroke in Asian Americans  
The first large scale observational study on AF conducted in mainland China on 29,000 
participants showed an incidence of 0.65% prevalence of AF in the community. This is 
surprisingly low considering that hypertension and diabetes are not rare, and this cohort included 
a small number of patients with rheumatic heart disease. Since only 2.7% received warfarin, they 
were able to determine the prevalence of stroke in un-anticoagulated AF patients which was 13% 
versus 2.3% risk in patients without AF. This 13% incidence includes a one-time visit with a 
single EKG, or perhaps going through prior medical records in patients who reported a history of 
AF..
45
 Therefore, although this shows that AF carries a high risk of stroke in Chinese patients, 
the incidence may be higher than what is reported in this study.   
Conversely, an American study by Kaiser Permanente in California looking at almost 
19,000 patients hospitalized for AF, where 3.9% were of Asian descent, found that Asians had 
lower rates of ischemic stroke compared to the other ethnicities in both the coumadin group and 
the no-coumadin group.
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 It is unknown if this difference between stroke risk in Chinese patients 
in China and in the U.S. is due to external factors, and need to be further studied with 
prospective studies that include Chinese Americans.  
 .It does appear that Asians are more prone to intracranial hemorrhage or hemorrhagic 
stroke than whites, blacks or Hispanics. Hemorrhagic stroke comprises 30% of all strokes in 
Asians which is much greater than other ethnic groups.
68
 When looking at AF patients on 
warfarin therapy in the Kaiser database, the Asian sub-group had a 15-fold increase in 
intracranial hemorrhage compared to Asians with AF who did not take coumadin.
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While blacks and Hispanics with AF on coumadin had roughly twice the rate of 
hemorrhagic stroke compared to white AF patients taking coumadin, Asian patients had 6 times 
the rate of hemorrhagic stroke compared to whites. Although there are studies showing that 
Asians tend to have genetic polymorphisms that make them more sensitive to warfarin therapy 
and require smaller doses, this study did not show that the increased risk of intracranial 
hemorrhage in the Asian subgroup was due to a greater incidence of supratherapeutic INR levels. 
The level of anticoagulation was similar between the groups so overanticoagulation in the non-
white subjects is not a likely explanation. These data along with the ethnic variation in AF as a 
risk factor for stroke suggest that there may be different risk/benefit ratios for different 
ethnicities when it comes to using warfarin.  
 
Race vs Ethnicity 
What are the implications of studying race or ethnicity with respect to a medical 
condition? What is the difference between race and ethnicity and is there an important distinction 
between the two when discussing a specific disease process? Ethnicity and race are often used 
interchangeably; however, generally speaking they are not the same thing. Ethnicity represents a 
social group with a shared history, geography and culture. People with different skin colors can 
belong to the same ethnic group. Race is a grouping of people based on physical characteristics 
such as skin color. Race is a social construct and not based on genetics or country of origin. 
There is, in fact, a lot of genetic diversity within racial groups. Nonetheless, race is typically 
what is reported in medical journal articles. It has also been used by investigators as a proxy for 
socioeconomic status or access to medical care. It is typically easier to acquire a person’s race 
which is now commonly self-reported and widely available in databases as compared to other 
demographics such as education level and zip code.  
Although it is a valid argument that race is not a good proxy for social and environmental 
factors which are more difficult to measure, race is an important means to measure health 
disparities. Race can serve as a first step when determining whether the relationship between 
outcomes and populations is truly related to race or other factors.
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For the medical community, one of the potential great promises of studying race is to 
help predict an individual’s medical history and assess risk factors for various disease processes. 
As race is now frequently reported, it is often considered a factor in an individual’s health. 
However, the notion that different racial groups share health-related genetic traits amongst 
themselves that differ from other groups is only theoretical at this point and has not been 
determined. In fact, all human beings share 99.9% of their genetic material. Whereas race is not 
based on genetics, ancestry does involve genetics more directly. Ancestry and race are only 
moderately correlated. However, ancestry can be very complicated with lineages form multiple 
regions of the globe and not as easy to report as race. Studies have shown that there is genetic 
variation between populations from Asia, Europe and Asia. Therefore, people from one region 
may have fewer differences than people form different regions. Although genetic ancestry and 
geographic ancestry do correlate, they are not synonymous and genetic similarities are found in 
people from neighboring regions.  
If genetic differences do exist between populations, it is likely due to either (1) the 
presence of genetic variants of susceptibility in one group but not another, (2) genetic variants of 
susceptibility vary in frequency between groups, or (3) some genetic variants have different 
effects on different populations. To really know whether different racial groups have differing 
risk factors based on genetic differences, a variant gene that is known to influence health should 
be studied in terms of frequency and effect among the different races.
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 The future promise of 
personalized risk assessment based on genetic testing will replace race as the tests become 
widely available and understood, and this will provide individual rather than group-based 
assessments. 
There are well documented disparities in the prevalence and incidence of multiple 
medical conditions in the U.S. such as obesity, HIV infection and hypertension. These conditions 
disproportionately affect minority groups. It is unknown what degree of influence is accounted 
for by genetic differences shared by individual racial groups. Many health disparities in fact are 
more strongly influenced by environment than genetics. Racial differences in access to health 
care, dietary choices and exposure to health hazards are well documented. In the U.S., minority 
groups tend to have less access to healthcare and services than Caucasian residents with 
disparities in treatment and outcomes demonstrated in a wide array of medical conditions 
including acute coronary syndrome and heart failure. It is very difficult to determine if there is 
any genetic causality and to what degree.  However, when looking at the incidence and 
prevalence of AF, Caucasians are disproportionately affected. Therefore, environmental factors 
such as health care disparities seem irrelevant or counter intuitive when talking about AF.  This 
makes the possibility of an underlying genetic difference more plausible. Only further large 
population studies can determine if there are any confounders not yet known such as younger age 
of African American subjects in the studies done so far.  
 
AF and Genetics 
Traditionally, AF has been thought of as a disease that is caused by environmental factors 
such as co-morbidities and underlying cardiac substrate, or caused by “bad luck” in the case of 
lone AF where the person has a structurally normal heart and no readily identifiable risk factors 
for AF.  Only in the recent past have studies revealed a probable link between genetics and AF. 
The offspring cohort of the Framingham Heart Study, which consisted of over 5000 individuals 
whose parents were enrolled in the Framingham Heart Study, was analyzed to assess whether 
parental AF had an effect on the risk of developing AF in their children. They found that a 
history of AF in at least one parent did increase the risk of AF in the next generation with an OR 
of 1.85 (p=0.02).
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 A genetic predisposition to AF was also shown in a population based genetic 
study done in Iceland by Dr. Arnar and colleagues. They used a national genealogical database 
and found that first degree relatives of those with AF had a 1.8 higher relative risk for AF 
compared to the general population. This relative risk increased to 4.7 when only looking at 
individuals younger than 60 years.
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In terms of identifying specific genes, Brugada and colleagues were the first to identify a 
genetic locus for AF.
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 They reported 3 families with autosomal dominant AF which linked to 
the genetic locus 10q22-24. Although they did not determine its exact genetic function, they 
hypothesized that it was possibly an ion channel or pore protein gene. Another genetic study 
looking at a single family of Chinese descent found a mutation on KCNQ1, which is the 
potassium channel IKS. They were able to map a serine to glycine missense mutation on 
chromosome 11 in affected family members.
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 There have been other reports by other 
investigators of autosomal dominant familial AF which localized to other loci, but these genetic 
mutations identified interestingly all correspond to an increase in potassium channel function 
which in turn shortens the atrial action potential duration and the atrial effective refractory period 
creating a favorable milieu for reentry and AF.
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 While autosomal dominant AF is rare, non-
autosomal dominant AF is probably more common.  
When looking at non-autosomal dominant AF, the genetic basis for AF is due to a genetic 
variant or polymorphism rather than a mutation. The majority of AF patients with a genetic 
predisposition fall into this category. Several investigators have looked at potassium channels in 
these patients with conflicting results which likely speaks to the multiple factors influencing the 
underlying mechanisms of AF. Dr. Arnar and his research team out of Iceland performed a 
genome-wide association scan in subjects of European descent and Chinese subjects living in 
Hong Kong. They found a strong association between two sequence variants on chromosome 
4q25 and AF in both ethnic groups. The risk of having AF was greater in the subjects with this 
variant approximately 1.5 times per copy of the genetic sequence.
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 Another Chinese study found 
that when studying the slow delayed rectifier potassium channel (Iks), a single nucleotide 
polymorphism in the K channel accessory subunit, KCNE4 had differences between the AF 
group and the control group.
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Aside from potassium channel subunits, researchers have also started looking at sodium 
channel subunits, sarcoplasmic reticulum calcium ATPase regulatory protein, the renin-
angiotensin system, and connexin 40. Although the studies are small in size, they are an 
intriguing groundwork for future studies. Clearly, future studies not only need to be larger, but 
need to be inclusive of different ethnic groups. A comprehensive review by Tsai and colleagues 
on the genetic studies of AF shows that all studies to date have been done in either Caucasians or 
Asians (predominantly Chinese).
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 A study of patients with diverse ethnic backgrounds with and 
without AF who are matched for AF risk factors could potentially shed light on important 
genetic markers and their interaction with risk factors for developing AF. A study like this may 
also elucidate which genetic changes are induced by environmental factors, and which genetic 
changes are due to a remodeling effect of the AF itself. Even if further genetic research shows 
that ion channel mutations are uncommon causes of AF, genetic studies with a broad ethnic 
population would detect possible genetic differences that correlate to prevalence and incidence 
differences among different populations.  
 
Inflammation and AF 
Inflammation, as detected as C-reactive protein (CRP), has also been implicated as a risk 
factor for developing AF.
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 It was also shown that CRP levels rise as AF burden increases, 
suggesting that persistent AF occurs in the setting of atrial inflammation.
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 Unfortunately, there 
are no studies looking at whether differences in CRP exist among different races. (For more 
details on inflammation and AF, please see Addendum.) 
 
Clinical Implications of Studying Race and AF 
The studies to date consistently show that whites have a higher prevalence of AF 
compared to other racial groups regardless of whether it is a heart failure cohort, stroke cohort, or 
a large out-patient database such as an HMO or the VA healthcare system. However, whites are 
consistently older than blacks and Hispanics in these same studies. One important question that 
needs to be addressed is,” Are non-whites truly less prone to develop AF or do Black patients die 
at a younger age than whites making the prevalence appear to be less? Or, are Blacks more likely 
to have heart failure and strokes than whites at a young age distorting the AF prevalence when 
looking at these groups? In other words, what seems to be an advantage might simply be a 
distorted narrow glimpse of a broader picture. These are difficult questions and would require a 
large prospective population study that is multi-racial. Large ethnically diverse cohorts such as 
the VA or Medicare could be studied prospectively as well.  
If there truly are differences in the prevalence of AF among the different racial groups, 
this would have tremendous implications for ongoing research on multiple levels. First, risk 
factor management has become an important part of cardiology clinical practice. If risk factor 
prevention could be tailored to specific groups of patients, this could greatly enhance prevention 
efforts. In addition, patients who are high risk for AF could have more aggressive screening for 
AF. For example, white patients over 65 years could need arrhythmia surveillance at more 
aggressive intervals than others, whereas black patients may need more aggressive hypertension 
screening and treatment algorithms than white patients. Second, the realm of genetics is still in 
its early stages. Although the medical community has to use this technology cautiously, it could 
potentially lead to medicine tailored not to certain groups, but to individuals. Another benefit of 
understanding the genetics behind AF is that it can be an area of promising treatment 
development down the road. Third, when different people respond to physiologic stress 
differently, this can be an opportunity to better understand the underlying pathophysiology. In 
other words, if one group of patients with a high prevalence of diabetes and hypertension has a 
low prevalence of AF, whereas another group with less diabetes and hypertension has a higher 
prevalence of AF, what is the underlying difference between the groups? Fourth, if we 
understood better how the different risk factors for AF actually cause AF, this would lead to a 
better understanding of the pathophysiology. While white patients with AF often have coronary 
disease, many black patients with AF have hypertension. Is the pathophysiology of 
atherosclerosis different from the pathophysiology of hypertension as a cause or predisposing 
factor for AF? Or perhaps there are unexplored environmental factors that differentiate the racial 
groups? There may also be racial differences for newer identified AF risk factors such as 
neurohormonal influences and inflammation. Lastly, if there is a difference in the development 
of AF between races, it raises the question of whether there are differences in stroke risk for 
patients with AF. Identifying a group at less risk than can be treated with a less aggressive 
treatment than systemic warfarin would be valuable information saving patients from the risks 
and inconvenience of warfarin.   
Since insufficient data are currently available on non-white patients, the most recent 
guidelines for AF, based on mostly white cohorts, should continue to be applied to other ethnic 
groups.  The ACC/AHA/ESC 2006 Guidelines for the management of patients with AF does 
state that based on limited data, “the age-adjusted risk of developing AF in blacks seems less 
than half that in whites”. There is no discussion, however, that much of the data presented is 
based on largely white cohorts. Although the Guidelines do not explicitly state that the 
recommendations apply to all patients, this is appropriate given the paucity of available of data.  
 
Implications for future research 
National research establishments such as the NIH and NHLBI have recognized the 
importance of enrolling female and minority patients in clinical research studies. The current 
focus on disparities in healthcare and outcomes only further underscores the insight that is gained 
by enrolling a diverse cohort and the limitations of extrapolating findings in one group to all 
patients. Although there have been large hypertension and heart failure clinical studies, they have 
yet to be leveraged to look for racial differences for other comorbidities such as AF. Future 
prospective population studies need to have a better representation of racial minorities to further 
explore differences that may exist in prevalence, treatment and outcome of many diseases such 
as AF. Lastly, future genetic studies should look at the genetics of not only whites, but also 
Blacks, Asians and Hispanics with the same clinical disease to assess for similarities and 
differences. Genetics holds the promise for moving beyond skin color to an individual’s genetic 
basis for disease susceptibility and prevalence.  
A prospective cohort study designed to detect racial differences in the risk of developing 
AF and the risk of having a stroke due to AF would be costly and lengthy. It is also difficult for a 
single study to capture all age groups, all races and a fair representation of women. However, 
there are already large, robust data sets available such as Medicare and the VA that are being 
used to prospectively collect data on other medical conditions. In addition, smaller case control 
retrospective studies can be done comparing a specific ethnic group to non-Hispanic white 
controls. Although a retrospective case control study is more susceptible to bias, it could provide 
an additional perspective by controlling for the confounding variables in the observational cohort 
studies presented in this review such as age, diabetes and hypertension. Lastly, more post hoc 
studies using a hypertension or diabetes randomized controlled trial data set would help confirm 




We included 11 studies in this review that examine the interaction of ethnicity and AF 
(Table 1). They are for the most part a mixture of prospective and retrospective cohort studies. 
Although they do vary in size and scope, they consistently show the incidence of AF to be lower 
in blacks compared to whites. In fact, we did not find any study that showed the incidence of AF 
to be equal to or greater than in whites. This difference in AF incidence appears to be 
irrespective of the prevalence of co-morbidities that increase the risk of developing AF. For 
example, most studies did show a greater prevalence of diabetes mellitus and hypertension in 
African Americans. Although many of the studies had a significant age differential with blacks 
being younger than whites, the difference in AF prevalence was maintained when age was 
controlled for in statistical regression models. 
We then included seven studies that examine the interaction of ethnicity and embolic 
stroke in patients with atrial fibrillation. Again, they were mostly prospective and retrospective 
cohort studies looking at the risk factors of patients who present with a documented stroke. The 
studies consistently showed that in patients with an acute ischemic stroke, the concomitant 
finding of AF was greater in whites compared to blacks. Similar to the AF studies, blacks tended 
to be younger with greater rates of hypertension. Some of the stroke cohort studies controlled for 
age to assess whether the difference in AF prevalence was simply a matter of the age differential 
between white and black, but the increased risk of having AF in whites persisted.  
 Prior historical population studies which first looked at the prevalence and incidence of 
AF in this country typically enrolled mostly white patients. Accordingly, the traditional statistics 
that are commonly used as a reference for prevalence and incidence as well as risk factors for 
developing AF are based on a white cohort. For example, the initial cohort in the Framingham 
Study which began in 1948 consisted of 5209 patients between the ages of 30 and 62, and was 
overwhelmingly white.
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 The Cardiovascular Health Study looked at a sample of over 5000 
patients over 65 years old who were Medicare recipients, however, only 4.7% were Black.
83
 And 
although statistics were done comparing men to women, no a priori analysis was done looking at 
race or ethnicity.  
 Due to the limitations of the studies in terms of a homogeneous population, the 2006 
ACC AHA ESC Guidelines on AF are only able to state that, “Based on limited data, the age-
adjusted risk of developing AF in blacks seems less than half than in whites.” This is based on 
just 3 studies.
5, 32, 36
  The EPOCH study is a retrospective look at the prevalence of AF in a heart 
failure population with Kaiser Permanente Health Insurance; the ATRIA study is also a 
retrospective look at AF patients in the same HMO; and the Cardiovascular Health Study is a 
prospective study looking at the incidence of AF in Medicare patients. The percent of blacks 
enrolled in these three studies were 16.2%, 3.6%, and 4.8% respectively. While ATRIA and 
EPOCH showed a significant difference in AF prevalence between black and white, the only 
prospective study looking at the incidence of AF, the Cardiovascular Health Study, did not find 
the difference to reach statistical significance. Since a large difference was found (Relative Risk 
for blacks developing AF was 0.47), the lack of statistical significance is very possibly due to the 
small percent of black patients in the study and lack of power.   
Heart failure studies that looked at AF similarly enrolled a predominantly Caucasian 
cohort. A post-hoc retrospective analysis of the SOLVD study which looked at the benefits of 
ACE-inhibitor in heart failure patients with left ventricular dysfunction was 98.4% Caucasian.
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The Consensus Trial, which also looked at the effect of ACE-inhibitor therapy in heart failure 
patients, was conducted in Scandinavia.
85
 Another example is the MERIT HF Trial which 
enrolled approximately 4,000 patients and had a prevalence of AF of 16-17%.
86
 Only 5% were 
black and the prevalence of AF was not broken down by race. These studies collectively are used 
to demonstrate the prevalence of AF in heart failure patients in the 2006 ACC/AHA/ESC 2006 
Guidelines for the Management of AF.
53
   
Although AF has been studied for decades, only recently has it become recognized as one 
of the most important cardiac conditions. This is due in part to its escalating prevalence and in 
part to the emerging ability to treat AF with catheter-based technology rather than anti-
arrhythmic or rate controlling medications. As we are learning more about the treatment for AF, 
understanding the pathophysiology and genetics of the disease also become more important. 
Understanding why someone with more traditional risk factors for AF is less likely to develop 
AF will likely lead us to some of these answers. Are there other risk factors that have yet to be 
explored? Is there an underlying factor that confers protection that needs to be explored? This 
paradoxical difference between whites and blacks as well as other minorities may mean that 
landmark population studies such as Framingham are not relevant for everyone and additional 
population studies need to be done with this in mind.  
To further our understanding of the differences in prevalence and incidence of AF among 
the different ethnic groups, further large population research is needed. For one, the Medicare 
database was already used in the Cardiovascular Health Study but blacks were underrepresented. 
Using a larger dataset of patients with a better representation of blacks as well as Hispanics and 
Asians will provide a clearer picture of true prevalence differences in patients 65 years and older. 
Looking at a relatively narrow range of ages (for example 65 to 80 years) will help ensure that 
the differences seen in prior studies is not due to a difference in mean age between groups. 
Secondly, leveraging other prospective ongoing database studies which have a large percentage 
of African Americans such as the ARIC study will provide insight into the incidence of AF 
specifically in the African American community. Third, genetic studies are becoming more and 
more an important aspect of understanding a disease process. All the genetic studies focusing on 
AF have been in either white or Chinese patients. Not only are more genetic studies needed, but 
genetic studies that include non-white patients. Genetic studies in black patients with and without 
AF may reveal significant differences in terms of which genes seem to be associated and which 
mutations are occurring. Lastly, differences between ethnic groups can only be discovered and 
researched further if the medical community makes a concerted effort in general to look at racial 
and ethnic differences. It has become fairly commonplace for studies to automatically do 
analyses based on sex, and the same should happen for ethnicity.   
In summary, in order to possibly some day risk stratify patients differently or prescribe 
medical therapy differently for whites versus the various minority groups, future clinical trials 
need to determine the morbidity and mortality of AF in these groups rather than assuming the 
Framingham data accurately reflects all groups. Specifically, future studies should address the 
following unanswered questions; 
1. What is the ischemic stroke risk for Black, Hispanic, and Asian patients with AF on 
aspirin and on coumadin?  
2. What is the relative risk of mortality for Black, Hispanic, and Asian patients with AF 
compared to Black, Hispanic, and Asian patients without AF? 
3. Is the paradox of AF incidence in Blacks and Whites real or is it due to confounding, 
particularly the older age and greater prevalence of coronary disease in whites? 
 
 Our review of the literature has several limitations. There were only 11 studies included 
with respect to the interaction of AF and ethnicity. Very few studies looking at AF have analyzed 
racial or ethnic differences and so there is a paucity of data in the literature. Only English 
language literature was used. Although our main focus was ethnic differences regarding AF in 
the U.S., it is possible that a non-English speaking European study looking at ethnic differences 
was overlooked. The selected studies are a mix of prospective and retrospective cohort studies 
lacking uniform data reporting. The studies also had a wide range of ages which impacts the 
incidence and prevalence of AF in all groups. The results are also subject to error since the 
determination of race was variable. In some studies race was self-reported, in others it was 
obtained from the insurance records or medical chart and may be incorrect.  
 Despite these limitations, the fact that various studies show a consistent difference 
despite differences in geographical location, age of enrolled subjects, and ethnic diversity of the 
population studied is valuable information. In aggregate, these studies do support the notion that 
there is a true difference rather than a sampling error or issues of under-reporting. This is 
especially true given the consistent findings and that many studies compare patients with the 
same insurance or living within similar geographic region which has been validated as a 
surrogate for socio-economic status.
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AF is the most common arrhythmia. The risk of developing AF increases with advancing 
age and the presence of other medical conditions including hypertension and diabetes mellitus. 
There are also additional risk factors more recently identified such as obesity and sleep apnea. 
When analyzing the data along ethnic lines, African Americans tend to have greater rates of 
hypertension, LVH and diabetes compared to white cohorts with lower rates of AF. When 
looking at the issue of AF from the angle of ischemic stroke, the etiology of the stroke is often 
hypertension in blacks and AF in whites. This ethnic difference has only recently been elucidated 
with the focus in the medical scientific community to look at issues of race and ethnicity as well 
as to improve the enrollment of minority populations. Genetics is a new area and has potential 
problematic uses for discrimination or racial profiling but also has merit and real promise in 
terms of helping medicine be tailored to individuals. Learning more about the differential risk of 
AF between ethnic groups has the potential to improve upon our understanding of the 
pathophysiology of AF in general.  
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A= Asian ACS= Acute Coronary Syndrome AF=atrial fibrillation B=black African American, DB=database CHF=congestive 
heart failure DM=Diabetes Mellitus, H=Hispanic, JACC=journal of the American College of Cardiology HMO=health 
maintenance organization JAMA=Journal of the American Medical Association JMNA=Journal of the National Medical 
Association NS=not significant OR=odds ratio RR=relative risk, W=white, Caucasian.   
Table 2 Quality Ratings for Studies Looking at the Interaction of Ethnicity and Atrial Fibrillation 
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A= Asian ACS= Acute Coronary Syndrome AF=atrial fibrillation B=black African American, BA= attrition bias, BM= 
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Mellitus, H=Hispanic, JACC=journal of the American College of Cardiology HMO=health maintenance organization 
JAMA=Journal of the American Medical Association JMNA=Journal of the National Medical Association NS=not significant 
OR=odds ratio RR=relative risk, W=white, Caucasian.  
 
 









Bush (2006)22 Post-hoc 















KM for time 
to endpoint 
B and H younger than whites. B had more 
HTN and less CAD than whites. Ischemic 
strokes were 5.7% H, 9.5% B, 6.1% W  
(p values not done) 
Overall survival did not differ among  



























Afro-Caribbeans had an OR for AF=0.27 































9% of Afro-Caribbeans and 34.8% of 
European Caucasians had AF p<0.001. 






















Black and white 
patients 
hospitalized 





11.2% of B and 32.4% of W had AF  
p<0.001, OR 0.28 when adjusted for age  
and other risk factors. B had  more strokes  
due to SVD (p<0.01), and W had more  






















>39 years old 








11% of B and H had AF, 29% of W  
(p<0.01 for W vs. B and vs. H). W  
patients were older with less HTN and  
heart disease.  

























B were younger with more HTN,  
DM, HF than W. OR for ICH in B=2,  























AF present in 25% W and 6.8% B  
(p<0.01). HTN and DM were more  
prevalent in B (p<0.001) 
 
A=Asian, AFFIRM=Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial, B= Black, African American, 
CAD=coronary artery disease, CE=cardioembolic source, H= Hispanic, HTN=hypertension, ICH= intracranial hemorrhage, 
JHH=Journal of Human Hypertension KM=Kaplan-Meier, OR=odds ratio, RCT=randomized controlled trial, SVD=small vessel 
disease, UK=United Kingdom, W=white, Caucasian. 
 
Table 4 Quality Ratings for Studies Looking at the Interaction of Ethnicity and Stroke 
 
Each Study is rated on a scale from 0 to 3. [0=poor, 1=fair, 2=good 3=excellent. Refer to 
Legend at end of Table 4 for further description] 
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AF=atrial fibrillation B=Black, DB=database H=Hispanic, HMO=Health Maintenance Organization 
ICH=intracranial hemorrhage RCT=randomized controlled trial W=white.  
  
Legend for Score Rating (0-3):  
 Source population adequately described?  
o Were data on hypertension, age, diabetes, heart failure, provided? 
o Were subjects with atrial flutter included (less rigorous)? 
o Was it described if the AF was paroxysmal or persistent? 
 Study Population representative? 
o Do the study subjects represent AF patients in the U.S.? 
o Are their confounding variables that make comparing the groups problematic?  
 Detection of AF and race determination adequate? 
o Was AF detected by routine EKG only or was more aggressive surveillance done? 
o Was race determined by the individual subjects (most reliable) or by the investigator, 
or the medical record (least reliable)? 
 Internal Validity adequate? 
o Did authors identify and adjust for confounders? 
o Was the study sufficiently powered? 
o Was cohort followed prospectively (more valid) or was data collected post hoc? 
 Follow-up and drop-out reported and reasonable? 
o Were all subjects followed (more robust) or only a percentage? 
o Were the drop-out rates reasonable and fairly equitable between the two groups? 
 Bias present?  
o Selection Bias: Was there a systematic difference between groups?  
o Performance Bias: Did the groups receive different medical care such as treatment for 
hypertension? 
o Detection Bias: Were the methods used to detect AF equal between groups? 











Master’s Paper Addendum: 
Inflammation and AF 
Using the large cohort from the Cardiovascular Health Study, Aviles et al determined that 
an elevated CRP level at baseline is predictive of an increased risk of developing new onset AF 
in the future although this is not necessarily a causal relationship.
88
 This remained true even after 
controlling for other risk factors for AF such as diabetes, hypertension, and advanced age. 
Although this cohort included an additional 687 black participants in addition to the original 
Health Study cohort which was 94% white, there was no breakdown of CRP by race. In addition, 
the analysis of race appeared to be divided into white and non-white, although presumably a 
large percentage of the non-white group was black. Another large prospective study looking at 
CRP levels in patients with and without AF also concluded that high CRP levels were predictive 
of an increased risk of AF later on. This study, the Intermountain Heart Collaborative Study, was 
done in a homogenous white population from the Salt Lake City, Utah region and so race was 
not factored into the analyses.
89
 Some European centers have also looked at the relationship 
between CRP and AF but had predominantly white cohorts, and race was therefore not described 
in the baseline patient characteristics
90-92
 Therefore, whether there are racial differences in CRP 
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